What is Histrelin?
Histrelin is a synthetic nonapeptide agonist of GnRH (LHRH) delivered via a unique 12-month subcutaneous hydrogel implant that releases drug at a controlled rate over a full year. Two FDA approvals:
- VANTAS — approved October 12, 2004 for palliative treatment of advanced prostate cancer; discontinued from US market in September 2021 for commercial reasons
- SUPPRELIN LA — approved May 3, 2007 for central precocious puberty (CPP) in children, and remains marketed as the standard implantable therapy for CPP
The 12-month implant duration is the longest of any GnRH agonist formulation, eliminating monthly or quarterly injection schedules. The implant is inserted in a brief outpatient procedure under local anesthesia and removed/replaced annually.
Structure and Mechanism
Histrelin's mechanism is identical to other GnRH agonists (goserelin, leuprolide, triptorelin):
- Continuous receptor activation downregulates pituitary GnRH receptors
- LH and FSH secretion is suppressed within 2-4 weeks
- Sex steroid production (testosterone or estradiol) falls to prepubertal levels
- In children with CPP, this halts pubertal progression and preserves adult height
The structural difference from native GnRH: D-histidine(N-benzyl) at position 6 (resistant to enzymatic cleavage) and N-ethylamide at the C-terminus.
Clinical Evidence
Phase 3 in central precocious puberty (JCEM 2007):
- 36 children with CPP randomized to histrelin implant
- 100% of patients achieved hormonal suppression within 1 month
- Stopped pubertal progression and improved predicted adult height
- Excellent tolerability over multi-year follow-up
Vantas in prostate cancer:
- Equivalent testosterone suppression to leuprolide and goserelin
- Annual implant exchange replaced more frequent injections
Approval History
- October 12, 2004 — FDA approval of Vantas for advanced prostate cancer (US-discontinued September 2021 for commercial reasons; not safety)
- May 3, 2007 — FDA approval of Supprelin LA for central precocious puberty in children ≥2 years
Place in Therapy
In CPP, Supprelin LA is a primary therapy alongside leuprolide depot. The annual implant offers:
- Excellent compliance — once-yearly outpatient procedure vs monthly intramuscular injections
- Stable hormonal suppression — no peaks/troughs as with depot injections
- Reversibility — implant removal allows resumption of normal puberty
The trade-offs are the requirement for a minor surgical procedure, slight implant-related local reactions, and the need to physically remove and replace the implant.
Safety Profile
Adverse events:
- Implant-site reactions (mild to moderate, transient)
- Initial brief gonadotropin surge with possible transient pubertal symptom worsening
- Hot flashes (in adolescents/adults)
- Rare cases of implant breakage requiring surgical retrieval
Long-term safety in pediatric CPP is well-established; histrelin has been used routinely in children since 2007 with no signal for adverse skeletal, growth, or fertility outcomes after discontinuation and resumption of natural puberty.
Why It Matters
Histrelin's once-yearly dosing established the benchmark for long-acting peptide depot delivery technology. The hydrogel implant principle has been extended to other peptide therapeutics in pediatric chronic disease, where adherence is challenging and minimizing injection burden has high value.